KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Equity Average (2018 - 2025)

Historic Equity Average for Bionano Genomics (BNGO) over the last 8 years, with Q3 2025 value amounting to $47.6 million.

  • Bionano Genomics' Equity Average fell 2633.61% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year decrease of 2633.61%. This contributed to the annual value of $65.8 million for FY2024, which is 6193.6% down from last year.
  • Bionano Genomics' Equity Average amounted to $47.6 million in Q3 2025, which was down 2633.61% from $46.8 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Equity Average registered a high of $354.3 million during Q2 2021, and its lowest value of $41.8 million during Q1 2025.
  • Its 5-year average for Equity Average is $187.3 million, with a median of $198.9 million in 2021.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 6647943.41% in 2021, then crashed by 6344.92% in 2024.
  • Quarter analysis of 5 years shows Bionano Genomics' Equity Average stood at $339.3 million in 2021, then decreased by 21.74% to $265.6 million in 2022, then plummeted by 59.49% to $107.6 million in 2023, then tumbled by 60.85% to $42.1 million in 2024, then grew by 12.98% to $47.6 million in 2025.
  • Its Equity Average stands at $47.6 million for Q3 2025, versus $46.8 million for Q2 2025 and $41.8 million for Q1 2025.